Literature DB >> 35764885

Dicer deficiency impairs proliferation but potentiates anti-tumoral effect of macrophages in glioblastoma.

Yu-Qi Liu1,2,3, Min Luo1,2, Yu Shi1,2, Ying Guo1,2, Hua Zhang1,2, Kai-Di Yang1,2, Tian-Ran Li1,2, Liu-Qing Yang1,2, Ting-Ting Liu4, Bo Huang4, Qing Liu1,2, Zhi-Cheng He1,2, Xiao-Ning Zhang1,2, Wen-Ying Wang1,2, Shuai Wang1,2, Hui Zeng1,2, Qin Niu1,2, Xia Zhang1,2, You-Hong Cui1,2, Zhi-Ren Zhang5, Xiu-Wu Bian6,7, Yi-Fang Ping8,9.   

Abstract

Glioblastoma is a lethal primary brain tumor with abundant immune-suppressive glioblastoma-associated macrophage (GAM) infiltration. Skewing immune suppressive GAMs towards an immune-activating phenotype represents a promising immunotherapeutic strategy against glioblastoma. Herein, we reported that genetic deletion of miRNA-processing enzyme Dicer in macrophages inhibited the growth of GL261 murine glioblastoma xenografts and prolonged survival of tumor-bearing mice. Single cell RNA sequencing (scRNA-seq) of the tumor-infiltrating immune cells revealed that Dicer deletion in macrophages reduced the proportion of cell-cycling GAM cluster and reprogramed the remaining GAMs towards a proinflammatory activation state (enhanced phagocytotic and IFN-producing signature). Dicer-deficient GAMs showed reduced level of cyclin-dependent kinases (CDK1 and CDK2) and increased expression of CDK inhibitor p27 Kip1, thus manifesting impaired proliferation. Dicer knockout enhanced phagocytotic activity of GAMs to eliminate GL261 tumor cells. Increased proinflammatory GAM clusters in macrophage Dicer-deficient mice actively interacted with tumor-infiltrating T cells and NK cells through TNF paracrine signaling to create a pro-inflammatory immune microenvironment for tumor cell elimination. Our work identifies the role of Dicer deletion in macrophages in generating an immune-activating microenvironment, which could be further developed as a potential immunotherapeutic strategy against glioblastoma.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35764885     DOI: 10.1038/s41388-022-02393-9

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  41 in total

1.  Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.

Authors:  Kurt A Schalper; Maria E Rodriguez-Ruiz; Ricardo Diez-Valle; Alvaro López-Janeiro; Angelo Porciuncula; Miguel A Idoate; Susana Inogés; Carlos de Andrea; Ascensión López-Diaz de Cerio; Sonia Tejada; Pedro Berraondo; Franz Villarroel-Espindola; Jungmin Choi; Alfonso Gúrpide; Miriam Giraldez; Iosune Goicoechea; Jaime Gallego Perez-Larraya; Miguel F Sanmamed; Jose L Perez-Gracia; Ignacio Melero
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

Review 2.  Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology.

Authors:  David H Gutmann; Helmut Kettenmann
Journal:  Neuron       Date:  2019-11-06       Impact factor: 17.173

Review 3.  Mechanisms of immunotherapy resistance: lessons from glioblastoma.

Authors:  Christopher M Jackson; John Choi; Michael Lim
Journal:  Nat Immunol       Date:  2019-07-29       Impact factor: 25.606

4.  A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis.

Authors:  Jing Zhang; Susobhan Sarkar; Rowena Cua; Yan Zhou; Walter Hader; V Wee Yong
Journal:  Carcinogenesis       Date:  2011-12-08       Impact factor: 4.944

5.  Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Authors:  James R Perry; Normand Laperriere; Christopher J O'Callaghan; Alba A Brandes; Johan Menten; Claire Phillips; Michael Fay; Ryo Nishikawa; J Gregory Cairncross; Wilson Roa; David Osoba; John P Rossiter; Arjun Sahgal; Hal Hirte; Florence Laigle-Donadey; Enrico Franceschi; Olivier Chinot; Vassilis Golfinopoulos; Laura Fariselli; Antje Wick; Loic Feuvret; Michael Back; Michael Tills; Chad Winch; Brigitta G Baumert; Wolfgang Wick; Keyue Ding; Warren P Mason
Journal:  N Engl J Med       Date:  2017-03-16       Impact factor: 91.245

Review 6.  Glioblastoma and other malignant gliomas: a clinical review.

Authors:  Antonio Omuro; Lisa M DeAngelis
Journal:  JAMA       Date:  2013-11-06       Impact factor: 56.272

7.  Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.

Authors:  Quinn T Ostrom; David J Cote; Mustafa Ascha; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

8.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

Authors:  Timothy F Cloughesy; Aaron Y Mochizuki; Joey R Orpilla; Willy Hugo; Alexander H Lee; Tom B Davidson; Anthony C Wang; Benjamin M Ellingson; Julie A Rytlewski; Catherine M Sanders; Eric S Kawaguchi; Lin Du; Gang Li; William H Yong; Sarah C Gaffey; Adam L Cohen; Ingo K Mellinghoff; Eudocia Q Lee; David A Reardon; Barbara J O'Brien; Nicholas A Butowski; Phioanh L Nghiemphu; Jennifer L Clarke; Isabel C Arrillaga-Romany; Howard Colman; Thomas J Kaley; John F de Groot; Linda M Liau; Patrick Y Wen; Robert M Prins
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

Review 9.  Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma.

Authors:  Stephen C Frederico; John C Hancock; Emily E S Brettschneider; Nivedita M Ratnam; Mark R Gilbert; Masaki Terabe
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

Review 10.  Immune Microenvironment in Glioblastoma Subtypes.

Authors:  Zhihong Chen; Dolores Hambardzumyan
Journal:  Front Immunol       Date:  2018-05-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.